Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06637423 · ClinicalTrials.gov registry record · Phase 1

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

A Phase 1 study of Non-muscle Invasive Bladder Cancer, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 1
Development phase
32
Enrollment target
13
Study locations

NCT06637423 is a Phase 1 study of Non-muscle Invasive Bladder Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 32 participants, below the 232-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (86% lower). The trial reports 13 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06637423, a Phase 1 study of Non-muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
13
Study locations

Study Summary

The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.

Conditions Studied

Non-muscle Invasive Bladder Cancer

Interventions

  • DRUG Supportive care measures
  • DRUG Sacituzumab tirumotecan
  • DRUG Rescue medication

Study Locations (13)

Val-de-Marne

  • HENRI MONDOR HOSPITAL ( Site 0011) - Créteil
  • Gustave Roussy ( Site 0013) - Villejuif

California

  • Michael G Oefelein Clinical Trials ( Site 0053) - Bakersfield

Florida

  • Moffitt Cancer Center ( Site 0057) - Tampa

Illinois

  • Northwestern University ( Site 0051) - Chicago

Maryland

  • Johns Hopkins University ( Site 0055) - Baltimore

Ontario

  • Princess Margaret Cancer Centre ( Site 0003) - Toronto

Quebec

  • CIUSSS de l'Estrie-CHUS ( Site 0002) - Sherbrooke

Nord

  • Hôpital Claude Huriez ( Site 0012) - Lille

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2024-12-20
Est. Completion 2028-07-31
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06637423

The ClinicalTrials.gov registry entry for NCT06637423 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Supportive care measures is the first listed.

NCT06637423 reports 13 study locations spanning 12 distinct geographic areas - top geographies include Val-de-Marne, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06637423 about?

NCT06637423 is a clinical study titled "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)". The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future ...

What is the current status of trial NCT06637423?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-12-20. Estimated completion is 2028-07-31.

What conditions does trial NCT06637423 study?

This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.

What interventions are being tested in trial NCT06637423?

The interventions under investigation include: Supportive care measures (DRUG), Sacituzumab tirumotecan (DRUG), Rescue medication (DRUG).

Who is sponsoring clinical trial NCT06637423?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06637423 being conducted?

This trial has 13 study locations across California, Florida, Illinois, Maryland, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-muscle Invasive Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-muscle Invasive Bladder Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.